title: In vitro fertilization cycle outcome after coasting in gonadotropin-releasing hormone (GnRH) agonist versus GnRH antagonist protocols.
abstract: OBJECTIVE
  To compare the results of IVF cycles after coasting in patients treated with a GnRH antagonist or GnRH agonist protocol.
  
  
  METHODS
  A retrospective case-control study.
  
  
  METHODS
  Infertility unit in a university-affiliated tertiary medical center.
  
  
  METHODS
  The study group included all women less than 38 years old attending the IVF unit from 2000 to 2006 in whom coasting was used. Data on E(2) levels before and after coasting, duration of coasting, number of oocytes retrieved and fertilized, embryo quality, moderate-severe ovarian hyperstimulation syndrome (OHSS), and pregnancy were collected from the files and compared between GnRH agonist (n = 329) and GnRH antagonist (n = 45) cycles.
  
  
  METHODS
  None.
  
  
  METHODS
  Number of retrieved oocytes and pregnancy rates.
  
  
  RESULTS
  There were no between-group differences in cycle parameters. In the antagonist group, there was no need for more than 2 days of coasting. There was a significant decrease in the number of retrieved oocytes even in short periods of coasting in the antagonist group but not in the agonist group. On the day of hCG administration, E(2) levels dropped to a lower level in the antagonist cycles. The OHSS rate after coasting was 4.6% in the agonist group and 4.4% in the antagonist group. Corresponding pregnancy rates after coasting were 27.4% and 24.4%.
  
  
  CONCLUSIONS
  The same criteria for coasting can be applied in GnRH agonist as in GnRH antagonist cycles, with a similar IVF result.
authors.affiliation: Department of Obstetrics and Gynecology, Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva, Israel. j_farhi@yahoo.com
authors.forename: Jacob
authors.initials: J
authors.lastname: Farhi
authors.forename: Avi
authors.initials: A
authors.lastname: Ben-Haroush
authors.forename: Yehezkel
authors.initials: Y
authors.lastname: Lande
authors.forename: Onit
authors.initials: O
authors.lastname: Sapir
authors.forename: Haim
authors.initials: H
authors.lastname: Pinkas
authors.forename: Benjamin
authors.initials: B
authors.lastname: Fisch
mesh_terms: D000328:Adult; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004958:Estradiol / Q000097:blood; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D005307:Fertilization in Vitro; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D008596:Menotropins / Q000008:administration & dosage; D054315:Oocyte Retrieval; D011247:Pregnancy; D018873:Pregnancy Rate; D012189:Retrospective Studies; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
chemical_list: D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D006727:Hormone Antagonists; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; D008596:Menotropins; D005640:Follicle Stimulating Hormone; C062876:cetrorelix